Full Press Release Details
Turn Therapeutics Appoints Veteran Capital Markets
Executive Andrew Scott as Vice President of Corporate Communications
Los Angeles, CA - November 4, 2025 - Turn
Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious
disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new
role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company's licensing
and partnership initiatives.
"We are thrilled to welcome Andrew to this
newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing
and strengthened balance sheet. Andrew brings a wealth of experience that will help guide us as a public company, expand our investor
engagement and ensure our story reaches the right audiences as we approach several important milestones in the coming year, including
the completion of our Phase 2 clinical program," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics.
"We look forward to Andrew's
guidance as we continue executing on partnerships and advancing our clinical development efforts."
With over 30 years of experience in capital markets and
corporate finance, Mr. Scott joins Turn Therapeutic from ThinkEquity LLC where he was a Managing Director of Investment Banking. Previously,
he served as Vice President of Business Development at Fortress Biosciences, Inc. Over the course of his career, he has helped raise approximately $3
billion across a wide range of transactions within the life-sciences sector. Mr. Scott received a BBA in Accounting from Pace University.
About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing
and commercializing products for dermatology, wound care, and infectious disease. The Company has received three FDA clearances for its
proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition,
Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting
its commitment to public health innovation.
Forward-Looking Statement
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other
than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained
in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "suggest," "target,"
"aim," "should," "will," "would," or the negative of these words or other similar expressions,
although not all forward-looking statements contain these words. Forward-looking statements are based on Turn's current expectations
and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success
of development programs and the Company's ability to execute its strategic plan. Further, certain forward-looking statements are
based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could
cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of
Turn Therapeutics in general, see the risk disclosures in the Company's filings with the Securities and Exchange Commission. All
such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements,
whether as a result of new information, future events, or otherwise.
Monique Kosse, Managing Director